General characteristics of the studies included (created by the authors)
| Category | Number of studies (N=100) | Number of comparisons (n=224) |
| Perspective* | ||
| Third-party payer | 83 | 175 |
| Societal | 21 | 40 |
| Patients | 4 | 9 |
| Model type | ||
| Markov | 96 | 216 |
| Discrete event simulation | 3 | 7 |
| Economic evaluation alongside clinical trial | 1 | 1 |
| Time horizon | ||
| Lifetime | 96 | 217 |
| Non-lifetime | 4 | 7 |
| Discount rate for cost | ||
| Not reported | 3 | 12 |
| ≤3% | 53 | 112 |
| >3% | 44 | 100 |
| Discount rate for utility* | ||
| Not reported | 3 | 11 |
| ≤3% | 58 | 134 |
| >3% | 40 | 79 |
| Clinical data source | ||
| Published literature | 81 | 181 |
| Published literature and evidence synthesis | 3 | 17 |
| Published literature and registry database | 11 | 18 |
| Evidence synthesis | 2 | 5 |
| Registry database | 3 | 3 |
| Utility data source | ||
| Published literature | 93 | 209 |
| Published literature and registry database | 4 | 11 |
| Survey | 3 | 4 |
| Currency year | ||
| 2008–2013 | 65 | 133 |
| 2014–2019 | 35 | 91 |
| Cost-effectiveness threshold | ||
| Country-specific | 73 | 172 |
| Gross domestic products-based | 23 | 45 |
| Others | 4 | 7 |
| Cost-effectiveness result* | ||
| Cost-effective | 84 | 166 |
| Not cost-effective | 24 | 58 |
*The total number of studies are more than 100 because individual studies applied multiple methods.